BIO-TECHNE Files 8-K on Operations & Financial Condition
Ticker: TECH · Form: 8-K · Filed: Feb 1, 2024 · CIK: 842023
| Field | Detail |
|---|---|
| Company | Bio-Techne Corp (TECH) |
| Form Type | 8-K |
| Filed Date | Feb 1, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-K, corporate-filing
TL;DR
**BIO-TECHNE just dropped an 8-K with fresh financials, time to check their numbers!**
AI Summary
BIO-TECHNE Corporation filed an 8-K on February 1, 2024, to report on its results of operations and financial condition, along with other events and financial statements. This filing, under the ticker TECH on NASDAQ, indicates the company is providing updated financial information to the public. For investors, this matters because it offers a fresh look into the company's financial health and recent performance, which can influence stock valuation and future investment decisions.
Why It Matters
This filing provides investors with the latest financial performance data for BIO-TECHNE, crucial for assessing the company's health and making informed investment decisions.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial information, not indicating any immediate new risks or significant changes.
Analyst Insight
A smart investor would review the detailed financial statements and results of operations once they become available to understand the company's current performance and financial health, using this 8-K as an alert for new information.
Key Players & Entities
- BIO-TECHNE Corporation (company) — the registrant filing the 8-K
- NASDAQ (company) — the exchange where BIO-TECHNE's Common Stock (TECH) is registered
- February 1, 2024 (date) — the date of the earliest event reported and filing date
- TECH (company) — the trading symbol for BIO-TECHNE's Common Stock
FAQ
What is the primary purpose of BIO-TECHNE Corporation's 8-K filing dated February 1, 2024?
The primary purpose of BIO-TECHNE Corporation's 8-K filing dated February 1, 2024, is to report on its 'Results of Operations and Financial Condition' and 'Other Events,' along with 'Financial Statements and Exhibits,' as indicated in the 'ITEM INFORMATION' section of the filing.
What is the trading symbol and exchange for BIO-TECHNE Corporation's Common Stock?
BIO-TECHNE Corporation's Common Stock trades under the symbol 'TECH' and is registered on 'NASDAQ,' as stated under 'Securities registered pursuant to Section 12(b) of the Act' in the filing.
What is the state of incorporation for BIO-TECHNE Corporation?
BIO-TECHNE Corporation's state of incorporation is 'Minnesota,' as specified in the 'State or Other Jurisdiction of Incorporation' section of the filing.
What is the business address and phone number of BIO-TECHNE Corporation?
The business address of BIO-TECHNE Corporation is '614 McKinley Place NE, Minneapolis, Minnesota 55413,' and its telephone number is '(612) 379-8854,' according to the filing's 'Address of Principal Executive Offices' and 'Registrant’s Telephone Number' sections.
Is BIO-TECHNE Corporation considered an emerging growth company according to this 8-K filing?
No, BIO-TECHNE Corporation is not considered an emerging growth company, as indicated by the unchecked box next to 'Emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934' in the filing.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 13.9 · Accepted 2024-02-01 06:30:00
Filing Documents
- tmb-20240201x8k.htm (8-K) — 35KB
- tmb-20240201xex99d1.htm (EX-99.1) — 548KB
- tmb-20240201xex99d2.htm (EX-99.2) — 21KB
- 0001558370-24-000683.txt ( ) — 757KB
- tmb-20240201.xsd (EX-101.SCH) — 3KB
- tmb-20240201_lab.xml (EX-101.LAB) — 15KB
- tmb-20240201_pre.xml (EX-101.PRE) — 11KB
- tmb-20240201x8k_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition A copy of the press release issued by Bio-Techne Corporation on February 1, 2024, describing the results of operations for the quarter ended December 31, 2023, and its financial condition as of December 31, 2023 is attached hereto as Exhibit 99.1. The information in this Form 8-K and the Exhibits attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Other Events
Item 8.01 Other Events A copy of the press release issued by Bio-Techne Corporation on February 1, 2024 announcing a cash dividend is attached hereto as Exhibit 99.2.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits 99.1 Press Release, dated February 1, 2024, announcing results of operations 99.2 Press Release, dated February 1, 2024, announcing cash dividend 104 - Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-TECHNE CORPORATION Date: February 1, 2024 By: /s/ Shane V. Bohnen Shane V. Bohnen Senior Vice President, General Counsel and Secretary